Consolidation ahead for pharma, Merck chief says

Sign Merck ($MRK) CEO Ken Frazier up for the no-megamergers pledge. At a financial conference, Frazier said he expects more consolidation in the pharma business because of a "redundancy of infrastructure," but Merck will focus on targeted deals to gain access to "the best of science" outside the company. Report